Navigation Links
Monogram Announces Third Quarter 2007 Financial Results
Date:10/24/2007

venues, especially during the first two quarters of 2006, included substantial revenues from the use of the Company's assays in Pfizer's phase III trial of maraviroc.

The net loss was $18.5 million, or $0.14 per common share, in the first nine months of 2007, compared to a net loss of $31.7 million, or $0.24 per common share, for the same period in 2006. Included in these results were substantial non-cash items, which are described below under "Non-GAAP Proforma Results." On a non-GAAP proforma basis, adjusted for these non-cash items, the net loss was $25.6 million, or $0.19 per share, in the first nine months of 2007 compared to a net loss of $15.3 million, or $0.12 per share, in the same period of 2006.

The Company had approximately $30 million in cash resources (comprised of cash, cash equivalents and short-term investments) at September 30, 2007.

Monogram's Trofile Assay and Pfizer's maraviroc

"This has been a pivotal quarter for our HIV business," said William Young, Monogram chief executive officer. "Several positive developments, including FDA approval of Pfizer's maraviroc, culminated in the commercial introduction of Trofile and the rapid establishment of coverage and reimbursement by Medicare. This important reimbursement benchmark bodes well for ongoing discussions with other public and private payers."

Pfizer has announced several positive developments for maraviroc, know as Selzentry(TM) in the U.S. and Celsentri(R), outside of the U.S. These include:

-- positive clinical results from 48 week follow up of patients enrolled

in both the phase III trial of maraviroc in treatment-experienced

patients and the separate trial in treatment-naive patients

-- approval, by both the FDA and the European Commission (EC), of

maraviroc for use in treatment-experienced patients selected by tropism

testing

-- availability, in mid September, of maraviroc throughout the U.S.

Monog
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 , Not ... in, into or from any jurisdiction where to do so ... jurisdiction.  Shire plc ("Shire" or the "Company") (LSE: ... this afternoon.  Shire confirms it has held a meeting with ... by Shire without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, and ... purchased a DNA test to unravel the ... a lifetime of memories, sharing, and closeness. In fact, ... genuinely brought the family closer together. , Recently, ... history and prior to taking the genetic ancestry ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... Inc. (Nasdaq: MYL ) today announced ... Biocon Limited, a publicly traded company on the ... the development, manufacturing, supply and commercialization of multiple, ... marketplace. Through this partnership, Mylan and Biocon bring ...
... June 29 , - Financing ... Gyros AB, the leading provider of ... SEK 80 million,(approximately euro 7.5 million) in an equity fundraising ... will enable Gyros to drive,the further commercialization of its Gyrolab ...
... , MENLO PARK, Calif., June 29 Kornberg Associates | ... Stanford University to design a new Cognitive & ... the announcement. The firm has worked with Stanford ... the past 30 years, one of which is the two-story, ...
Cached Biology Technology:Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 2Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 3Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 4Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 2Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 3Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 4Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center 2
(Date:7/11/2014)... South Wales, Australia when NASA,s Aqua satellite passed overhead ... 11 (12:35 p.m. local time/11:35 p.m. EDT on July ... (NSW), the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard captured ... smoke (light brown) from various fires. Actively burning areas, ... , The New South Wales, Australia Government website "NSW ...
(Date:7/11/2014)... release is available in German . ... a method that uses the refraction of X-rays through ... images produced with this method are often of much ... in the team of Prof. Franz Pfeiffer are particularly ... and therapy including X-ray phase-contrast imaging. One main ...
(Date:7/11/2014)... Researchers from Salk Institute for Biological Studies, BGI, ... the safety and reliability of the existing targeted ... method, TALEN-HDAdV, which could significantly increased gene-correction efficiency ... study published online in Cell Stell Cell ... cell-based gene therapy. , The combination of stem ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... may have just gotten a little louder. Researchers ... genes under control of in living things than suspected only ... model organism is dramatically higher than previously reported. The new ... "This new finding may help to explain why ...
... blasts in Hiroshima and Nagasaki, Japan, in 1945, likely ... thyroid cancer as adults, according to Japanese researchers. ... Research , a journal of the American Association for ... close to the blast sites, were comparably young at ...
... Researchers report the discovery of the first new living species ... to be published online on August 28th in Current ... that the new species, called Tridacna costata , once ... the Red Sea, it now represents less than one percent ...
Cached Biology News:Study shows more genes are controlled by biological clocks 2Study shows more genes are controlled by biological clocks 3Researchers discover atomic bomb effect results in adult-onset thyroid cancer 2New giant clam species offers window into human past 2
... system uses a burst of high-pressure ... acid-coated gold or tungsten microparticles to ... or organelles without dependence or interaction ... includes helium pressure regulator, solenoid, spacer ...
... system, 220-240 V, is used for ... The system includes the BioLogic LP ... MV-6 injection valve, proportioning valve or ... and fittings kit, column and conductivity ...
Sf21 Insect Cells (Frozen) in Max-XP Medium...
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
Biology Products: